Keryx Kidney Disease Treatment Shows Promising Results in Phase 2 Trial
NEW YORK -- Biotech company Keryx Biopharmaceuticals Inc. said Thursday its mid-stage trial of a kidney disease treatment showed positive results.
The company said the drug, Zerenex, was well tolerated, safe and effective in people with end-stage kidney disease at the optimum dose of 6 grams per day.
The patients were undergoing hemodialysis. None of the more than 100 patients in the 28-day study died or had serious adverse effects that could be definitely linked to Zerenex, the company said.
Keryx rose 36 cents, or 3 percent, to $13 in midday trading on the Nasdaq. In the past 52 weeks, the stock has traded between $12.27 and $19.35.
NEW YORK -- Biotech company Keryx Biopharmaceuticals Inc. said Thursday its mid-stage trial of a kidney disease treatment showed positive results.
The company said the drug, Zerenex, was well tolerated, safe and effective in people with end-stage kidney disease at the optimum dose of 6 grams per day.
The patients were undergoing hemodialysis. None of the more than 100 patients in the 28-day study died or had serious adverse effects that could be definitely linked to Zerenex, the company said.
Keryx rose 36 cents, or 3 percent, to $13 in midday trading on the Nasdaq. In the past 52 weeks, the stock has traded between $12.27 and $19.35.
posted by doublezero at
5:18 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home